Curing Kids Cancer Through Collaboration



"The importance of the goals, the dedication and organization of the planning process, and the integrity and promise of the vision is what makes all of us committed to serve on The Nicholas Conor Institute Board of Directors."
- John Wooley Ph.D. Associate Vice Chancellor of Research, University of California- San Diego

Board of Directors

Beth Anne Baber, PhD MBA - Co-Founder & Chief Executive Officer
Beth Anne has more than 20 years of academic experience in molecular biology, neurobiology, cell biology, developmental biology, cancer biology, and signal transduction. Her research focused on the understanding of the molecular mechanisms involved in DNA damage repair following treatment with radiation and chemo-therapeutic agents. Her work in DNA damage signaling has led to publications in major scientific journals, including Nature and Science. The National Institute of Health, the Leukemia and Lymphoma Society and the Beckman Laser Institute funded Beth Anne’s research initiatives.

While at the Salk Institute, her son, Nicholas Conor, was diagnosed in 2005 with high-risk neuroblastoma. Beth Anne and her husband, Michael N. Boddy (a Faculty member at The Scripps Research Institute), challenged the current treatment protocol for high-risk MYC-N non-amplified neuroblastoma patients by tailoring their son's therapy based on molecular markers versus relying on clinical pathology. As a result, Nicholas Conor has been cancer free for 5 years with no detectable long-term side effects. In 2007 following her son’s treatment, Beth Anne co-founded TNCI. While completing her MBA studies at the UCSD Rady School of Management, she developed an innovative business model, TACTiCTM (The Acceleration of Cancer Treatments in Children), to move discoveries that would benefit children with cancer out of academia and into commercialization. TACTiCTM has been featured in PricewaterhouseCoopers’ Personalized Medicine publications, the Burrill Report, California Health Institute’s Biomedical Industry 2010 Report, and FasterCures’ Partnering for Cures 2010 conference. Beth Anne is an inaugural member of the TNCI Board of Directors, served as VP of Operations from 2007 to 2009 and currently, the Institute’s CEO. Under her leadership, TNCI has formed collaborations with AltheaDx, CollabRx, GeneKey, Life Technologies, Gydle, Molecular Response, National Cancer Institute and CureSearch for Children’s Cancer.

Beth Anne received a DLA Piper-Athena Full Scholarship to attend the UCSD Rady School of Management where she earned her MBA (Business Development and Marketing) in 2009. Additionally, Beth holds a PhD (Macromolecular Cellular Structure and Chemistry) from The Scripps Research Institute - La Jolla Kellogg School of Science and Technology, a Masters in Microbiology and Immunology from University of North Carolina-Chapel Hill, and a Bachelors of Science (Biology) from the University of North Carolina-Chapel Hill.

Clare Livingston (Bud) Bromley III
Bud has a track record of entrepreneurial leadership spanning three decades.   He was the senior business development, marketing and sales executive and an officer at four public corporations, each company a supplier of high technology for life sciences.  Prior to those positions, his 18 year career at Hewlett-Packard Company included worldwide sales responsibility for Bioscience Products, Global Accounts and the International Olympic Committee and international management assignments in Japan and Latin America.  Currently, he consults for a virtual drug discovery company and is on the scientific advisory board at the Vancouver Prostate Centre’s Laboratory for Advanced Genome Analysis.

Elizabeth Estes
Elizabeth is Executive Vice President Chief Strategy Officer of GA Communication. She spends every day immersed in today’s multi-faceted media world by creating, shaping and directing  business and communication strategies along with multi-channel media efforts for the clients of the Chicago-based agency. Her unique skill set is borne out of 20+ years in broadcast media, including Director of News/Talk/Sports Programming for 11 News/Talk and Sports Radio Stations for Clear Channel Communications.   Elizabeth was principal and co-founder of JHG, a San Diego-based digital agency that focused on digital and mobile channels. JHG’s clients included the NFL, Yahoo, Comcast, Rogers Communications and Qualcomm, among others. In 2009, JHG was acquired by GA Communication. Elizabeth is currently pioneering a role working with healthcare and pharmaceutical organizations and their quest to reach both consumers and healthcare professionals, while managing around the absence of current FDA guidelines.
Morton Freedman
 Morton (Mort), a native of Philadelphia, PA, entered his career in real estate as a broker in Chicago, IL, in 1969, from where he moved to Arizona in 1971 to start Nationwide Resources Corporation. While in Arizona, Mort volunteered his time among numerous community projects. Specifically, Mort was appointed to the United Way board for one year by the Mayor of Tucson, as well as to the Chamber of Commerce. Mort also served for ten years on board of the Jewish Federation, as well as the Chairman of the Combined Jewish Appeal, a fund raising arm for the Jewish Community. Mort served for 11 years on the board of the Steele Memorial Children's Research Center, initially as a founding member, followed by chairman of the advisory committee. He has overseen the growth of a nascent research-focused organization to a well-funded and fully integrated research center for pediatric diseases. Mort has a Bachelor of Arts Degree from Temple University.
Tony Hunter, PhD
Tony is an ACS Professor, Director of the Molecular and Cell Biology Laboratory and the Cancer Center at the Salk Institute. His current efforts are understanding mechanisms of signal transduction and its role in cell growth and cancer, using a variety of experimental systems. Currently, he serves on the editorial boards of several journals. He has received many awards, including a NCI Outstanding Investigator Award, the Katharine Berkan Judd Award, the General Motors Cancer Research Foundation Mott Prize, a Gairdner Foundation International Award, the Biochemical Society Hopkins Medal, the Feodor Lynen Medal, the J. Allyn Taylor International Prize in Medicine, the Keio Medical Science Prize, the City of Medicine Award, the ACS Medal of Honor, the Landon-AACR Prize for Cancer Research, the Prince of Asturias Award for Scientific and Technical Research, the Louisa Gross Horwitz Prize, and the Wolf Prize in Medicine.  He is a Fellow of the Royal Society of London, an Associate Member of the EMBO, a Fellow of the American Academy of Arts and Sciences, a Member of the National Academy of Sciences, a Member of the Institute of Medicine, and a Member of the American Philosophical Society.
Brian Kelley
Brian is the managing Partner and CFO for Paradigm Investment Group, a company that is currently ranked in the top 100 franchised businesses within the United States.  Additionally, Brian is an owner and CFO of Dovovan’s Steak & Chop House and Paradigm Reality Group, LLC.  He currently holds the position of President for the Independent Hardee’s Franchise Association, representing over 1200 restaurants. Stemming from his passion for sports and children, he contributes his time and expertise to various Boards and committees, including San Diego’s Hall of Champions, San Diego Sports Medicine Foundation for Children, and the Gonazalez Family Sports Academy. Brian majored in Business Economics at Brown University and earned his MBA from the University of Southern California.

Martin Latterich, PhD - Co-Founder & Chief Scientific Officer
Martin brings over 17 years of academic, commercial and technology development experience to The Nicholas Conor Institute. He is also a Professor at the Proteogenomics Research Institute for Systems medicine in San Diego, where his laboratory uses proteomics and genomics to discover novel biomarkers of cancer and degenerative disease though a systems biology approach that includes proteomics and genomics. His area of interest is in the personalization of therapies that take into consideration a patient’s unique physiology and genetic make-up when selecting a treatment. The ultimate hope of this approach is to reduce the toxicity of treatment while optimizing its efficacy.

The paradigm of personalized medicine promises to be applicable to the field of pediatric oncology. Martin’s role at TNCI is on discovering new technologies to enable the better treatment of children with cancer, matching their unique genetic make-up and tumor physiology to available treatment options. It is this approach that is central to the Mission of the Institute – discovering and applying new scientific approaches designed to effectively treat cancer while minimizing the toxicity of the treatments.

Martin previously served on the faculties of the University of Montreal, McGill University and the Salk Institute. He also held senior management position at several biotechnology companies, including the genome companies Illumina and Diversa. He has made significant contributions to the field of cell biology, clinical biomarker discovery, proteomics and genomics. Among his recent discoveries are biomarkers for cancer, respiratory disease and neurodegenerative disorders. Martin hopes that after rigorous clinical studies, some of these biomarkers can be utilized as future molecular diagnostic assays to enable personalized medicine. Martin’s grant-funded work has been recognized by the 2003 Tier I Canada Research Chair, the 1998 Pew Scholar Award and the 1997 Basil O'Connor Starter Scholar Award. He has edited one book on RNAi, is author on over 32 publications in leading scientific journals and is listed on numerous patent applications. He is Editor-in-Chief of the scientific journal Proteome Science. He was a postdoctoral fellow in molecular and cell biology in the laboratory of Dr. Randy Schekman at the HHMI and University of California, Berkeley. Dr. Latterich earned his Ph.D. in cell biology and a B.Sc. in biochemistry and molecular biology from Durham University, U.K.
Janet Vohariwatt
Janet is the CEO and founder of iChanneX Corporation. Prior to founding iChanneX, she served as VP Global Product Development at Inasoft, a start-up company, Vice President of SAIC, a $6B Technology Integration Company, Xerox Corporation, and Ford Aerospace Telecom Subsidiary-Starnet. Janet has led teams in developing innovative IT solutions for customers such as Kaiser Permanente, Saskatchewan Provincial Health, Department of Defense Health Services, and BellSouth Wireless among many others. Janet believes strongly in community services and globalization; she serves on the Sharp HealthCare Foundation Board of Directors and is a mentor for the UCSD Rady School of Management Mentor Program. In 2006, she received the San Diego Women Who Mean Business Award.

Past Directors

Geoffrey M. Wahl, PhD
Geoff is a professor in the Gene Expression Laboratory at the Salk Institute and an Adjunct Professor at the University of California, San Diego in the Department of Biology.  He obtained a B.A. in Bacteriology from the University of California, Los Angeles and a PhD in Biological Chemistry from Harvard University, where he studied with Dr. Mario Capecchi. He was a postdoctoral fellow at Stanford University in the laboratory of Dr. George Stark. He joined The Salk Institute and became Professor in the Gene Expression Laboratory in 1989. His research focuses on two important problems related to cancer biology. The first concerns the signal transduction pathways that ensure the control of genetic stability in normal cells and are invariably disrupted during cancer progression.  A second project involves determining relationships between the “state of stemness” and cancer. Geoff has published more than 150 articles and reviews related to genetic instability, p53 functions, the control of DNA replication, and has several in submission related to the stem cell state and cancer. He has contributed to the development of numerous technologies in wide use in molecular and cellular biology and holds a number of patents. He serves as a reviewer for major biomedical journals, is on several editorial Boards, and has taken an active role in increasing public knowledge of, and funding for, cancer research. He was elected President of the American Association for Cancer Research, the largest and oldest cancer research organization in the world, for 2006-2007.
John Wooley, PhD
John is Associate Vice Chancellor of Research at the University of California at San Diego and a founding member of The Nicholas Conor Institute.  He is a leader in bringing computers and biology together. He created the first programs within the U.S. government for funding research in bioinformatics and computational biology. This effort included collaborating on the first stages of the genome project. In his position as Associate Vice Chancellor of Research at UCSD, his primary responsibilities as part of the campus academic leadership team are establishing priorities and undertaking new initiatives, and developing and implementing new research and training programs in science and engineering. He is also an Adjunct Professor at the university in pharmacology, chemistry and biochemistry, and a strategic advisor and Senior Fellow of the San Diego Supercomputer Center. For the new UCSD California Institute for Telecommunication and Information Technology, John directs the biology and biomedical applications component, termed Digitally-enabled Genomic Medicine, a step in delivering personalized medicine in a wireless clinical setting.
Elizabeth Keene Alton

Beth is the founder and  the President of Keene Solutions, a firm that provides outsourced human resource support, management coaching, training and advises non-profit clients on board governance issues. Beth spent nearly 20 years in the non-profit, bio-research sector with the Salk Institute for Biological Studies in La Jolla, CA. Her most recent role was that of Vice President, Human Resources.  She currently serves on the Board of Directors for the National Postdoctoral Association, as the Chair of Board Development, has served on the board of the San Diego Biotechnology Employment Development Coalition and on the San Diego Employers Association Advisory Council.

David Geerdes

David is an Attorney at Law and former Of Counsel for Procopio Cory Hargreaves & Savitch and Management Attorney for Gray Cary Ware & Freidenrich and Heller Ehrman, LLP, advising clients on all aspects of management organization, business strategies, employee matters, negotiations, litigation strategy and avoidance. David was appointed to serve on the Commission on Financing the Infrastructure by the Mayor of San Diego and the San Diego Commission on Government Efficiency and Restructuring appointed by the County Board of Supervisors. In addition to many other community activities, David was the Legal Advisor to Board of Trustees and Executive Committee for the Salk Institute, general counsel for the San Diego Convention and Visitors Bureau and Past President, Member of Board of Directors and Executive Committee of the San Diego County Taxpayers Association.

3525 Del Mar Heights Road, #946 • San Diego, California 92130
(858) 945-0552 •